Patient-derived xenografts : a promising resource for preclinical cancer research
Patient-derived xenograft tumors retain molecular and histopathological features of the originating tumor and are useful preclinical tools for drug discovery and assessment. We recently reported that 'rapid' engraftment of head and neck squamous cell carcinoma samples is highly prognostic and correlates with deregulation of the G1/S checkpoint. Tumors with genetic alterations in cyclinD1 (CCND1) and/or cyclin-dependent kinase inhibitor 2A (CDKN2A) are more likely to respond to abemaciclib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Molecular & cellular oncology - 6(2019), 1 vom: 14., Seite 1558684 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karamboulas, Christina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abemaciclib |
|---|
| Anmerkungen: |
Date Revised 29.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1080/23723556.2018.1558684 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294135480 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294135480 | ||
| 003 | DE-627 | ||
| 005 | 20231225080833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/23723556.2018.1558684 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0980.xml |
| 035 | |a (DE-627)NLM294135480 | ||
| 035 | |a (NLM)30788424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karamboulas, Christina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient-derived xenografts |b a promising resource for preclinical cancer research |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Patient-derived xenograft tumors retain molecular and histopathological features of the originating tumor and are useful preclinical tools for drug discovery and assessment. We recently reported that 'rapid' engraftment of head and neck squamous cell carcinoma samples is highly prognostic and correlates with deregulation of the G1/S checkpoint. Tumors with genetic alterations in cyclinD1 (CCND1) and/or cyclin-dependent kinase inhibitor 2A (CDKN2A) are more likely to respond to abemaciclib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Patient-derived xenografts | |
| 650 | 4 | |a abemaciclib | |
| 650 | 4 | |a biomarker discovery | |
| 650 | 4 | |a engraftment | |
| 650 | 4 | |a head and neck squamous cell carcinoma | |
| 650 | 4 | |a preclinical tool | |
| 700 | 1 | |a Ailles, Laurie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular & cellular oncology |d 2014 |g 6(2019), 1 vom: 14., Seite 1558684 |w (DE-627)NLM245054391 |x 2372-3556 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2019 |g number:1 |g day:14 |g pages:1558684 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/23723556.2018.1558684 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2019 |e 1 |b 14 |h 1558684 | ||